An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)

Trial Profile

An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs SRX 246 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Sponsors Azevan Pharmaceuticals
  • Most Recent Events

    • 14 Jun 2016 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
    • 14 Jun 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
    • 14 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top